Novo Nordisk shares fall as obesity pipeline faces investor scrutiny

Novo Nordisk shares fell as much as 3.5% after detailed trial data for its experimental obesity drug CagriSema raised investor concerns regarding its tolerability, showing slightly more nausea than rival treatments, and its delayed launch timeline of early 2027. This fuels skepticism about Novo's competitiveness against Eli Lilly's pipeline, especially as Lilly's oral weight-loss candidate orforglipron presented positive early safety data. Analysts now view Novo as a 'fast follower' in the lucrative obesity market, a significant shift underscored by previous efficacy disappointments for CagriSema and recent executive changes aimed at addressing the company's perceived loss of first-mover advantage.

Analysis

Novo Nordisk's shares declined by as much as 3.5% following the release of detailed late-stage trial data for its experimental obesity drug, CagriSema. The data fueled investor skepticism regarding Novo's ability to compete with Eli Lilly, primarily due to tolerability concerns and a delayed launch timeline. Specifically, CagriSema demonstrated slightly higher instances of nausea compared to Novo's own Wegovy and Lilly's Zepbound, an issue analysts at Jefferies termed "incremental." Furthermore, the drug's projected launch in early 2027 is viewed as a significant delay, eroding its competitive edge. This contrasts sharply with positive sentiment surrounding Eli Lilly, which reported no safety issues in a mid-stage trial for its oral weight-loss candidate, orforglipron, with pivotal late-stage data anticipated in the third quarter. The market is repositioning Novo Nordisk from an "obesity leader to a fast follower," a sentiment reinforced by previous disappointments, including CagriSema's failure in December 2024 to meet its 25% weight loss target and the subsequent ousting of the CEO. The company's stock has fallen approximately 55% from its June 2024 peak, reflecting a significant re-rating of its market leadership.

Key Decisions for Investors

• Given the persistent concerns over CagriSema's competitive profile, including its tolerability and delayed 2027 launch, investors should exercise caution with Novo Nordisk and scrutinize its ability to defend its market share against Eli Lilly's advancing pipeline.
• The divergent performance and pipeline news flow between Novo Nordisk and Eli Lilly may warrant a strategic portfolio review, potentially favoring exposure to Lilly, which is exhibiting stronger near-term momentum and fewer development hurdles with its oral candidate.
• Monitor Eli Lilly's upcoming late-stage data for orforglipron in the third quarter, as a positive outcome could further solidify its perceived leadership in the obesity market and intensify pressure on Novo Nordisk's valuation and strategic outlook.